CEL-SCI Co. (NYSEAMERICAN:CVM)’s share price rose 8.6% on Tuesday . The stock traded as high as $8.79 and last traded at $8.75, approximately 860,199 shares traded hands during trading. An increase of 21% from the average daily volume of 710,681 shares. The stock had previously closed at $8.06.

CEL-SCI (NYSEAMERICAN:CVM) last announced its earnings results on Tuesday, May 14th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The business had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.10 million.

Several hedge funds and other institutional investors have recently bought and sold shares of CVM. Thoroughbred Financial Services LLC increased its stake in shares of CEL-SCI by 21.1% in the first quarter. Thoroughbred Financial Services LLC now owns 13,921 shares of the company’s stock valued at $49,000 after buying an additional 2,428 shares during the period. Captrust Financial Advisors purchased a new position in shares of CEL-SCI during the 2nd quarter valued at about $25,000. Steward Partners Investment Advisory LLC purchased a new position in shares of CEL-SCI during the 2nd quarter valued at about $25,000. Endurance Wealth Management Inc. purchased a new position in shares of CEL-SCI during the 2nd quarter valued at about $29,000. Finally, Advisor Group Inc. raised its stake in shares of CEL-SCI by 16.6% during the 2nd quarter. Advisor Group Inc. now owns 38,923 shares of the company’s stock valued at $327,000 after buying an additional 5,545 shares during the last quarter.

CEL-SCI Company Profile (NYSEAMERICAN:CVM)

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Featured Story: How to Invest in Marijuana Stocks

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.